Nanomedicines accessible in the market for clinical interventions
Copyright © 2020 Elsevier B.V. All rights reserved..
Nanomedicines refers to nanotechnology inspired pharmaceutical products often referred to as 'nanopharmaceuticals.' It has displayed commendable potential in enhancing therapeutic efficacy as well as in reducing the side effects associated with conventional drug counterpart. Recent years have monitored the entry of a large amount of nanomedicine in the market with an appreciable market share to date. Despite this, the development of nanomedicine is posing challenges (i.e., safety, regulatory hurdles, cost, scale-up issues, etc.) that need to be resolved for their market entry. This review presents a cross-sectional discussion on the nanomedicine-derived products available in the market for both clinical and diagnostic applications. An overview of its market potential, market size, and the products that are currently in the clinical stages is also provided. The review also expounds on the challenges faced by nano-drug products at the time of their commercialization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:330 |
|---|---|
| Enthalten in: |
Journal of controlled release : official journal of the Controlled Release Society - 330(2021) vom: 10. Feb., Seite 372-397 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gadekar, Vedant [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trials |
|---|
| Anmerkungen: |
Date Completed 07.07.2021 Date Revised 07.07.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jconrel.2020.12.034 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319347907 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319347907 | ||
| 003 | DE-627 | ||
| 005 | 20231225171246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jconrel.2020.12.034 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1064.xml |
| 035 | |a (DE-627)NLM319347907 | ||
| 035 | |a (NLM)33370576 | ||
| 035 | |a (PII)S0168-3659(20)30758-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gadekar, Vedant |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanomedicines accessible in the market for clinical interventions |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.07.2021 | ||
| 500 | |a Date Revised 07.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a Nanomedicines refers to nanotechnology inspired pharmaceutical products often referred to as 'nanopharmaceuticals.' It has displayed commendable potential in enhancing therapeutic efficacy as well as in reducing the side effects associated with conventional drug counterpart. Recent years have monitored the entry of a large amount of nanomedicine in the market with an appreciable market share to date. Despite this, the development of nanomedicine is posing challenges (i.e., safety, regulatory hurdles, cost, scale-up issues, etc.) that need to be resolved for their market entry. This review presents a cross-sectional discussion on the nanomedicine-derived products available in the market for both clinical and diagnostic applications. An overview of its market potential, market size, and the products that are currently in the clinical stages is also provided. The review also expounds on the challenges faced by nano-drug products at the time of their commercialization | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a Drug delivery | |
| 650 | 4 | |a Marketed product | |
| 650 | 4 | |a Nanomedicines | |
| 650 | 4 | |a Regulatory issues | |
| 650 | 4 | |a Scale-up | |
| 700 | 1 | |a Borade, Yogeshwari |e verfasserin |4 aut | |
| 700 | 1 | |a Kannaujia, Suraj |e verfasserin |4 aut | |
| 700 | 1 | |a Rajpoot, Kuldeep |e verfasserin |4 aut | |
| 700 | 1 | |a Anup, Neelima |e verfasserin |4 aut | |
| 700 | 1 | |a Tambe, Vishakha |e verfasserin |4 aut | |
| 700 | 1 | |a Kalia, Kiran |e verfasserin |4 aut | |
| 700 | 1 | |a Tekade, Rakesh K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of controlled release : official journal of the Controlled Release Society |d 1996 |g 330(2021) vom: 10. Feb., Seite 372-397 |w (DE-627)NLM085820296 |x 1873-4995 |7 nnns |
| 773 | 1 | 8 | |g volume:330 |g year:2021 |g day:10 |g month:02 |g pages:372-397 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jconrel.2020.12.034 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 330 |j 2021 |b 10 |c 02 |h 372-397 | ||